Previous Study: TRIO027
Next Study: TRIO022

Studies & Results


Phase II randomized study of pembrolizumab with or without epigenetic modulation with CC-486 in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

View FDA Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at